

Mania after termination of epilepsy treatment: a case report

Like many other medical conditions, epilepsy itself increases the risk of psychiatric disorders. Underlying neurological dysfunction due to epilepsy may predispose to psychiatric disorders.^{1,2} There is a similarity between epilepsy and Bipolar Disorder (BD) as they are both episodic, chronic disorders treated with antiepileptic drugs (AEDs) such as valproic acid and carbamazepine (CMZ).³ However, data on epidemiology and the relationship between epilepsy and mood disorders, is limited to unipolar depression.^{1,2,4}

The patient, a 16-year-old Caucasian female, was brought to the emergency department by her mother with complaints of excessive talking, hyperactivity and decreased need for sleep of two weeks duration. According to her mother, the patient became progressively more agitated, irritable, euphoric, loquacious, and inappropriately jocular in the preceding two days and wandered the house getting nervous about the noises of children she claimed to have in her head. Reviewing her medical history, it was determined that she had a history of cerebral palsy and mild mental retardation. She had been treated with CMZ for complex partial epilepsy from her birth until two months earlier when the medication was stopped following a 7 year seizure-free period. She had never had an affective episode before.

In the psychiatric evaluation she was restless and irritable, fully oriented but distractible. She showed flight of ideas, loosened associations and grandiose delusions. Her neurological examination, laboratory studies, cranial magnetic resonance imaging and electroencephalogram were normal. She was diagnosed with a manic episode with psychotic features.⁵ This manic episode took place after stopping CMZ.

The patient was followed weekly as an outpatient. 400 mg/day CMZ was prescribed again and 2 mg/day risperidone was commenced due to the psychotic features. Her manic symptoms resolved within two weeks, with a blood CMZ level of 8.1 µg/ml. Her affect was euthymic and she had no psychiatric symptoms other than ones related to mild mental retardation and cerebral palsy (poor ability to abstract, impaired communication and fine motor deficits). The patient was followed on a monthly basis for the first 3 months and risperidone was stopped due to a symptom-free period while 400 mg/day CMZ was continued with a prophylactic blood concentration of 8–10 µg/ml. The follow-up intervals were increased to 6 months and for 2 years she had no recurrence.

Informed consent was obtained from her mother to publish the case material on an anonymous basis.

Medical comorbidities are common in BD^{1,2} while psychiatric problems are often observed in epilepsy, especially mood and affective disturbances.^{2,6} In this patient, the time of onset of manic symptoms - without a history of BD - suggests a relationship with the termination of CMZ treatment. CMZ had served as a mood stabilizer as well as an AED for this patient and she was thus

thought to have both epilepsy and BD.

Although depression is the most common affective disorder seen in epilepsy^{2,6} data on the relationship between manic episodes and epilepsy is limited. This raises the question of whether manic episodes in epilepsy are truly rare, or if the AEDs used to treat the disorder suppress the emergence of manic episodes.³ The recognition of manic episodes, and by definition BD, in such a situation may thus be difficult.⁴ The kindling phenomenon, irregularities in neurotransmitters and voltage gate ion channels and secondary messenger systems are shared biochemical and pathophysiological underpinnings in the etiology of both these chronic, episodic disorders.^{7,8,9} However, in contrast to epilepsy, only some AEDs are curative for BD and no animal model can adequately match the mood swings.^{9,10} Understanding the pharmacodynamics of these common curative AEDs could improve the understanding of the pathophysiology of both conditions^{3,8} and BD should be considered in the treatment of an affective episode during epilepsy.

B Ersoz Alan¹, D Unal²

¹Clinic of Child and Adolescent Psychiatry, Dr. Sami Ulus Maternity and Children's Health and Diseases Training and Research Hospital, Altindag, Ankara, Turkey

²Department of Child and Adolescent Psychiatry, Hacettepe University School of Medicine, Sıhhiye, Ankara, Turkey

References

1. Kanner AM. The complex epilepsy patient: intricacies of assessment and treatment. *Epilepsia* 2003; 44 (Suppl. 5): 3–8.
2. Pellock JM. Defining the problem: psychiatric and behavioral comorbidity in children and adolescents with epilepsy. *Epilepsy & Behavior* 2004; 5: 3–9.
3. Mula M, Marotta AE, Monaco F. Epilepsy and bipolar disorders. *Expert Rev Neurother* 2010; 10: 13–23.
4. Strakowski SM, McElroy SL, Keck Jr PE, et al. The co-occurrence of mania with medical and other psychiatric disorders. *Int J Psychiatr Med* 1994; 24:305–328.
5. American Psychiatric Association: *Diagnostic and statistical manual of mental disorders, 4th edition, Text Revision (DSM-IV-TR)*. Washington (DC): American Psychiatric Association 2000.
6. Robertson MM. Mood disorders associated with epilepsy. *Psychiatric Comorbidity in Epilepsy*, Connell HW, Snyder PJ (Ed), Washington, DC: American Psychiatric Press Inc, 1998: 133–169.
7. Post RM, Weiss SR. Kindling and stress sensitization. In: Young LT, Joffe RT, eds. *Bipolar Disorder - Biological Models and their Clinical Application*. New York, NY: Marcel Dekker, 1997: 93–126.
8. Rogawski M, Loscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. *Nat Med* 2004; 10: 685–692.
9. Grunze HC. Anticonvulsants in bipolar disorder. *J Ment Health* 2010; 19: 127–141.
10. Machado-Vieira R, Kapczinski F, Soares JC. Perspectives of the development of animal models of bipolar disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 2004; 28: 209–224.

Correspondence

Dr B Ersoz Alan
email: burcuerso02@gmail.com